These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 7238443)

  • 21. Lymph-node-negative oestrogen-receptor-positive breast cancer.
    Pansegrau GK; Gelmon KA
    Lancet; 2004 Sep 4-10; 364(9437):820-1. PubMed ID: 15351171
    [No Abstract]   [Full Text] [Related]  

  • 22. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer.
    Pesce C; Liederbach E; Wang C; Lapin B; Winchester DJ; Yao K
    Ann Surg Oncol; 2014 Oct; 21(10):3231-9. PubMed ID: 25081341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
    Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
    Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer.
    Lee ES; Han W; Kim MK; Kim J; Yoo TK; Lee MH; Lee KH; Kim TY; Moon HG; Im SA; Noh DY; Lee ES
    BMC Cancer; 2016 Jul; 16():430. PubMed ID: 27388210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
    Jakesz R; Hausmaninger H; Haider K; Kubista E; Samonigg H; Gnant M; Manfreda D; Tschurtschenthaler G; Kolb R; Stierer M; Fridrik M; Mlineritsch B; Steindorfer P; Mittlböck M; Steger G
    J Clin Oncol; 1999 Jun; 17(6):1701-9. PubMed ID: 10561206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term survival in primary breast cancer: correlation with estrogen and progesterone receptor assay results and adjuvant tamoxifen therapy.
    Chrapusta SJ; Giermek J; Pieńkowski T
    Med Sci Monit; 2004 Oct; 10(10):CR577-86. PubMed ID: 15448598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes.
    Orr RK; Col NF; Kuntz KM
    Surgery; 1999 Sep; 126(3):568-76. PubMed ID: 10486611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.
    Dignam JJ; Dukic V; Anderson SJ; Mamounas EP; Wickerham DL; Wolmark N
    Breast Cancer Res Treat; 2009 Aug; 116(3):595-602. PubMed ID: 18830816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
    Sopik V; Sun P; Narod SA
    Breast Cancer Res Treat; 2017 Sep; 165(2):391-402. PubMed ID: 28601929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The estrogen receptor test: a prognostic tool in primary breast cancer.
    Logan LA; Cripps MC; Hirte WE; Rapp EF
    Can J Surg; 1982 Sep; 25(5):581-4. PubMed ID: 7116258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
    Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Adjuvant hormonal therapy in lymph node-negative breast carcinoma patients in the postmenopause].
    Kurz C; Scholten C; Zielinski C; Czerwenka K; Kubista E; Spona J; Sevelda P
    Dtsch Med Wochenschr; 1992 Dec; 117(51-52):1943-6. PubMed ID: 1478168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oestrogen receptors and survival in early breast cancer.
    Croton R; Cooke T; Holt S; George WD; Nicolson R; Griffiths K
    Br Med J (Clin Res Ed); 1981 Nov; 283(6302):1289-91. PubMed ID: 6794823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.
    Owusu C; Buist DS; Field TS; Lash TL; Thwin SS; Geiger AM; Quinn VP; Frost F; Prout M; Yood MU; Wei F; Silliman RA
    J Clin Oncol; 2008 Feb; 26(4):549-55. PubMed ID: 18071188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experience with a simple method for estrogen receptor assay in breast cancer.
    Liskowski L; Rose DP
    Clin Chim Acta; 1976 Mar; 67(2):175-82. PubMed ID: 2401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant systemic therapy in breast cancer. Part 1: Adjuvant hormone therapy.
    Boyages J; Tiver KW
    Aust N Z J Surg; 1992 May; 62(5):354-63. PubMed ID: 1575655
    [No Abstract]   [Full Text] [Related]  

  • 38. Are there changes in characteristics and therapy of young patients with early-onset breast cancer in Germany over the last decade?
    Banz-Jansen C; Heinrichs A; Hedderich M; Waldmann A; Wedel B; Mebes I; Diedrich K; Rody A; Fischer D
    Arch Gynecol Obstet; 2013 Aug; 288(2):379-83. PubMed ID: 23407999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
    Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.